Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucose homeostasis in statin users-The LIFESTAT study

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Morville, T, Dohlmann, T, Kuhlman, AB, Monberg, T, Torp, M, Hartmann, B, Holst, JJ, Larsen, S, Helge, JW & Dela, F 2019, 'Glucose homeostasis in statin users-The LIFESTAT study', Diabetes - Metabolism: Research and Reviews (Print Edition), vol. 35, no. 3, pp. e3110. https://doi.org/10.1002/dmrr.3110

APA

Morville, T., Dohlmann, T., Kuhlman, A. B., Monberg, T., Torp, M., Hartmann, B., Holst, J. J., Larsen, S., Helge, J. W., & Dela, F. (2019). Glucose homeostasis in statin users-The LIFESTAT study. Diabetes - Metabolism: Research and Reviews (Print Edition), 35(3), e3110. https://doi.org/10.1002/dmrr.3110

CBE

Morville T, Dohlmann T, Kuhlman AB, Monberg T, Torp M, Hartmann B, Holst JJ, Larsen S, Helge JW, Dela F. 2019. Glucose homeostasis in statin users-The LIFESTAT study. Diabetes - Metabolism: Research and Reviews (Print Edition). 35(3):e3110. https://doi.org/10.1002/dmrr.3110

MLA

Vancouver

Morville T, Dohlmann T, Kuhlman AB, Monberg T, Torp M, Hartmann B et al. Glucose homeostasis in statin users-The LIFESTAT study. Diabetes - Metabolism: Research and Reviews (Print Edition). 2019 Mar;35(3):e3110. https://doi.org/10.1002/dmrr.3110

Author

Morville, Thomas ; Dohlmann, Tine ; Kuhlman, Anja B ; Monberg, Tine ; Torp, Mimmi ; Hartmann, Bolette ; Holst, Jens J ; Larsen, Steen ; Helge, Jørn W ; Dela, Flemming. / Glucose homeostasis in statin users-The LIFESTAT study. In: Diabetes - Metabolism: Research and Reviews (Print Edition). 2019 ; Vol. 35, No. 3. pp. e3110.

Bibtex

@article{e3f0bf5198224e3eabde32d009b2490b,
title = "Glucose homeostasis in statin users-The LIFESTAT study",
abstract = "BACKGROUND: Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.METHODS: We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross-sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non-myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non-statin users.RESULTS: A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non-myalgic group (AUC ISROGTT , C: 1032 (683 - 1500); M: 922 (678 - 1091); NM: 1089 (933 - 1391) pmol·L-1 ·min (median with 25%-75% percentiles), but no other measurements indicated impaired β-cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.CONCLUSIONS: We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non-users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.",
keywords = "Cardiovascular Diseases/prevention & control, Cross-Sectional Studies, Female, Follow-Up Studies, Glucose Intolerance/drug therapy, Glucose Tolerance Test, Homeostasis, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Insulin Resistance, Male, Middle Aged, Prognosis",
author = "Thomas Morville and Tine Dohlmann and Kuhlman, {Anja B} and Tine Monberg and Mimmi Torp and Bolette Hartmann and Holst, {Jens J} and Steen Larsen and Helge, {J{\o}rn W} and Flemming Dela",
note = "{\textcopyright} 2018 John Wiley & Sons, Ltd.",
year = "2019",
month = mar,
doi = "10.1002/dmrr.3110",
language = "English",
volume = "35",
pages = "e3110",
journal = "Diabetes - Metabolism: Research and Reviews",
issn = "1520-7552",
publisher = "John/Wiley & Sons Ltd",
number = "3",

}

RIS

TY - JOUR

T1 - Glucose homeostasis in statin users-The LIFESTAT study

AU - Morville, Thomas

AU - Dohlmann, Tine

AU - Kuhlman, Anja B

AU - Monberg, Tine

AU - Torp, Mimmi

AU - Hartmann, Bolette

AU - Holst, Jens J

AU - Larsen, Steen

AU - Helge, Jørn W

AU - Dela, Flemming

N1 - © 2018 John Wiley & Sons, Ltd.

PY - 2019/3

Y1 - 2019/3

N2 - BACKGROUND: Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.METHODS: We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross-sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non-myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non-statin users.RESULTS: A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non-myalgic group (AUC ISROGTT , C: 1032 (683 - 1500); M: 922 (678 - 1091); NM: 1089 (933 - 1391) pmol·L-1 ·min (median with 25%-75% percentiles), but no other measurements indicated impaired β-cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.CONCLUSIONS: We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non-users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.

AB - BACKGROUND: Statins are widely used to lower cholesterol concentrations in both primary and secondary prevention of cardiovascular disease. The treatment increases the risk of muscle pain (myalgia) and of type 2 diabetes. However, the underlying mechanisms remain disputed.METHODS: We investigated whether statin induced myalgia is coupled to impaired glucose homeostasis using oral glucose tolerance test (OGTT), intravenous glucose tolerance test (IVGTT), and the hyperinsulinemic euglycemic clamp. We performed a cross-sectional study of statin users without CVD (primary prevention) stratified into a statin myalgic (M; n = 25) and a non-myalgic (NM; n = 39) group as well as a control group (C; n = 20) consisting of non-statin users.RESULTS: A reduction in the insulin secretion rate during the OGTT was observed in the myalgic group compared with the non-myalgic group (AUC ISROGTT , C: 1032 (683 - 1500); M: 922 (678 - 1091); NM: 1089 (933 - 1391) pmol·L-1 ·min (median with 25%-75% percentiles), but no other measurements indicated impaired β-cell function. We found no other differences between the three groups for other measurements in the OGTT, IVGTT, and euglycemic clamp. Muscle protein content of GLUT4 and hexokinase II was similar between the three groups.CONCLUSIONS: We conclude that statin users in primary prevention experiencing myalgia do not have impaired glucose homeostasis compared with other statin users or non-users. We consider this an important aspect in the dialogue between physician and patient regarding statin treatment and adverse effects.

KW - Cardiovascular Diseases/prevention & control

KW - Cross-Sectional Studies

KW - Female

KW - Follow-Up Studies

KW - Glucose Intolerance/drug therapy

KW - Glucose Tolerance Test

KW - Homeostasis

KW - Humans

KW - Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use

KW - Insulin Resistance

KW - Male

KW - Middle Aged

KW - Prognosis

U2 - 10.1002/dmrr.3110

DO - 10.1002/dmrr.3110

M3 - Journal article

C2 - 30517978

VL - 35

SP - e3110

JO - Diabetes - Metabolism: Research and Reviews

JF - Diabetes - Metabolism: Research and Reviews

SN - 1520-7552

IS - 3

ER -

ID: 59410901